Summit Therapeutics Inc.
Oncology biotech developing ivonescimab, a PD-1/VEGF bispecific, across multiple global Phase 3 lung and colorectal cancer programs.
Oncology · PD-1/VEGF bispecific antibody · BLA under FDA review + Phase 3
Oncology biotech developing ivonescimab, a PD-1/VEGF bispecific, across multiple global Phase 3 lung and colorectal cancer programs.
Oncology · PD-1/VEGF bispecific antibody · BLA under FDA review + Phase 3